Skip to main content

Table 3 Relation between clinico-pathological parameters and immunohistochemistry of E-cadherin, β-cadherin, and S100A4 at invasive margin in colorectal cancers (n = 305)

From: Combined aberrant expression of E-cadherin and S100A4, but not β-catenin is associated with disease-free survival and overall survival in colorectal cancer patients

Parameters E-cadherin P β-cadherin P S100A4 P
  Strong (n = 208) Weak or Loss (n = 97)   Nuclear, Low (n = 267) Nuclear, High (n = 38)   Low (n = 267) High (n = 267)  
Preoperative CEA (ng/ml) 7.0 ± 22.5 6.5 ± 12.4 0.811 6.5 ± 19.8 8.4 ± 18.3 0.573 5.3 ± 13.1 12.5 ± 35.7 0.014
MSI status (n = 166)    0.167   0.004    0.386
 MSI-H (n = 8) 3(37.2) 5(62.5)   8(100.0) 0(0.0)   7(87.5) 1(12.5)  
 MSI-L (n = 6) 3(50.0) 3(50.0)   4(66.7) 2(33.3)   5(83.3) 1(16.7)  
 MSS (n = 135) 91(67.4) 44(32.6)   107(81.1) 25(18.9)   107(80.5) 26(19.5)  
Tumor Location    0.455   0.037    0.704
 Right (n = 66) 48(72.7) 18(27.3)   *6.5 ± 18.7   60(87.0) 9(13.0)  
 Left (n = 236) 158(66.9) 78(33.1)   *12.2 ± 22.7   194(84.0) 37(16.0)  
Tumor Budding   0.011   0.799   0.480
 Low (<10) (n = 263) 188(70.9) 77(29.1)   230(87.1) 34(12.9)   224(85.2) 39(14.8)  
 High (≥ 10) (n = 40) 20(50.0) 20(50.0)   37(90.2) 4(9.8)   32(80.0) 8(20.0)  
Macroscopic Tumor Type    0.616   0.909    0.038
 Polypoid (n = 21) 17(77.3) 5(22.7)   18(85.7) 3(14.3)   21(100.0) 0(0.0)  
 Ulcerofungating (n = 160) 109(66.9) 54(33.1)   143(88.3) 19(11.7)   138(86.3) 22(13.8)  
 Ulceroinfiltrative (n = 122) 82(68.3) 38(31.7   106(86.9) 16(13.1)   97(79.5) 25(20.5)  
Tumor Grade   0.735   0.817   0.577
 Well (n = 73) 53(72.6) 20(27.4)   64(86.5) 10(13.5)   60(82.2) 13(17.8)  
 Moderate or Poor (n = 227) 151(66.5) 73(34.0)   196(87.5) 28(12.5)   191(85.3) 33(14.7)  
Ratio of Metastatic Lymph Node 0.11 ± 0.19 0.13 ± 0.21 0.567 0.12 ± 0.20 0.09 ± 0.19 0.317 0.11 ± 0.19 0.18 ± 0.23 0.019
Nodal Stages   0.567   0.288   0.002
 N0 (n = 178) 128(70.3) 54(29.7)   155(85.2) 27(14.8)   161(90.4) 17(9.6)  
 N1 (n = 77) 49(63.6) 28(36.4)   69(92.0) 6(8.0)   57(74.0) 20(26.0)  
 N2 (n = 48) 31(67.4) 15(32.6)   43(89.6) 5(10.4)   38(79.2) 10(20.8)  
Depth of Invasion   0.513   1.000   0.010
 T1, T2 (n = 50) 38(73.1) 14(26.9)   44(88.0) 6(12.0)   48(96.0) 2(4.0)  
 T3, T4 (n = 253) 170(67.2) 83(32.8)   223(87.5) 32(12.5)   208(82.2) 45(17.8)  
AJCC stage   0.272   0.669   0.001
 I (n = 39) 27(67.5) 13(32.5)   35(87.5) 5(12.5)   37(94.9) 2(5.1)  
 II (n = 133) 96(71.1) 39(28.9)   114(85.1) 20(14.9)   119(89.5) 14(10.5)  
 III (n = 110) 74(68.5) 34(31.5)   97(89.8) 11(10.2)   81(73.6) 29(26.4)  
 IV (n = 21) 11(50.0) 11(50.0)   21(91.3) 2(8.7)   19(90.5) 2(9.5)  
Lymphovascular Invasion   0.891   0.341   0.050
 Negative 150(68.5) 69(31.5)   195(88.6) 25(11.4)   189(87.1) 28(12.9)  
 Positive 57(67.1) 28(32.9)   72(84.7) 13(15.3)   66(77.6) 19(22.4)  
Neural Invasion   0.037   0.507   0.050
 Negative 196(69.8) 85(30.2)   248(87.9) 34(12.1)   240(85.7) 40(14.3)  
 Positive 11(47.8) 12(52.2)   19(82.6) 4(17.4)   15(68.2) 7(31.8)  
Lymphocyte infiltration   0.325    0.821   < 0.0001
 Mild 70(72.9) 26(27.1)   88(88.9) 11(11.1)   70(71.4) 28(28.6)  
 Moderate 108(67.1) 53(32.9)   138(86.3) 22(13.8)   144(89.4) 17(10.6)  
 Severe 26(60.5) 17(39.5)   36(87.8) 5(12.2)   38(95.0) 2(5.0)  
Type of Tumor Growth   0.159   1.000   0.044
 Expanding 79(73.1) 29(26.9)   93(87.7) 13(12.3)   96(90.6) 10(9.4)  
 Infiltrative 125(65.1) 67(34.9)   168(87.0) 25(13.0)   156(81.3) 36(18.8)  
  1. Lymph Node Ratio, number of metastatic lymph nodes / number of harvested lymph nodes; CEA carcinoembryonic antigen serum level, *, percentage of β-catenin nuclear expression at invasive margin.